Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Further Reading from MarketBeat.com Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsAuthored by Nathan Reiff. Publication Date: 3/12/2026. 
Key Points - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: Elon Musk's $1 Quadrillion AI IPO
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to reach $366 billion within the next eight years. Companies often take a niche approach, developing medicines that target a specific cancer type with particular mechanisms. Several promising treatments have shown strong potential—and with that comes the possibility of significant sales. Two smaller biotech companies are seeing notable share-price momentum thanks to their leading oncology medicines. Beyond offering powerful treatment potential, these drugs could help the firms move beyond volatile small-cap status toward greater stability and, possibly, long-term profitability. That said, both companies still face meaningful challenges, making them typical high-risk biotech investments that could generate outsized rewards for investors willing to accept the risk. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle Dressed head to toe in black, she was known as The Witch of Wall Street—Hetty Green was ridiculed for her frugality, but when banks were collapsing in the Panic of 1907, she quietly wrote a check for $1.1 million to keep the National Bank of Commerce afloat, and when New York City couldn't meet payroll in 1898, it was Hetty who saved them. Her most famous investment was during the Civil War when the Union printed colossal quantities of paper greenbacks that dropped as low as 50 cents against the gold-backed dollar, but Hetty predicted the government would honor their debts and bought up all the greenbacks she could get, making an absolute fortune worth tens of millions in today's money when the U.S. government redeemed them at face value. What Erez and I have discovered is a modern-day equivalent of this trade—a multi-billion asset hiding inside a boring blue-chip stock Wall Street has completely mispriced, an asset worth more than the entire business itself but invisible on the books, and five major catalysts are converging with the first one recently triggered. Get the full story here now Iovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% during a week when the S&P 500 slipped about 1%. That added to Iovance's year-to-date performance, which has more than doubled. Still, with a consensus price target of $8.88, Wall Street implies roughly 71% upside from current levels. The primary catalyst for Iovance's price movement is Amtagvi, a T-cell immunotherapy approved for certain types of melanoma. Amtagvi has been approved in the United States since 2024 and is gaining traction in sales, with additional approvals likely in the E.U., U.K., and elsewhere. When administered with Proleukin, the company's IL-2 immunotherapy, management believes Amtagvi could exceed $1 billion in peak U.S. sales. Amtagvi's broader potential may extend beyond melanoma: the drug received FDA Fast Track Designation for non-small cell lung cancer and is being evaluated for other indications as well. Part of Iovance's outperformance this year also stems from its Q4 2025 earnings report issued in late February, in which the company reported a smaller-than-expected loss per share and $5 million in revenue. For the full year, revenue rose about 30% year over year. Iovance is still a relatively small biotech (about $2 billion market cap), and despite its recent rally analysts remain cautious — roughly half of its dozen analyst ratings are Hold or Sell. Risks remain high: beyond the usual caveats for smaller biotechs, Amtagvi's personalized, costly and complex manufacturing process could limit margins and complicate scaling, potentially constraining profitability even as demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, but its year-to-date performance dwarfs Iovance's. IBRX shares are up nearly 300% so far in 2026, and analysts remain optimistic: the consensus price target of $13.60 implies roughly 70% upside from current levels. ImmunityBio's lead product is Anktiva, a treatment for certain types of bladder cancer. In February, shares jumped after the E.U. regulator granted conditional marketing authorization — the latest in a series of approvals worldwide. Anktiva is driving the firm's revenue growth, generating $113 million in sales last year — roughly a 700% year-over-year increase. Like Amtagvi, Anktiva may have potential in additional cancer types, and ImmunityBio is actively exploring other indications. Despite the dramatic run-up over recent quarters, IBRX remains a speculative and risky investment. The company posted a sizable full-year net loss of $351 million for 2025 as R&D expenses continue to mount. Still, Wall Street analysts are relatively bullish: six of seven analysts currently rate the shares a Buy or equivalent. | 
